Physician profile
Aparna A Kamat
NPI 1992732887
$116,130.24
in general payments reported to CMS, 2019-2025
44 companies · $1,369 in 2025
The $1,369 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $15K · 2021: $28K · 2022: $26K · 2023: $10K · 2024: $638 · 2025: $1,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,940 · Food and Beverage: $3,035 · Travel and Lodging: $150 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,940.00 |
| Food and Beverage | $3,035.40 |
| Travel and Lodging | $150.00 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $46,207.95 | 2020-2025 | Keytruda, Lynparza |
| Tesaro, INC. | $34,098.62 | 2019 | |
| Glaxosmithkline, LLC. | $29,242.64 | 2019-2025 | Zejula, Jemperli |
| Aspira Women'S Health INC | $1,811.02 | 2019-2024 | Ova1 |
| Astrazeneca Pharmaceuticals LP | $847.13 | 2019-2025 | Lynparza |
| Myriad Genetic Laboratories, INC. | $555.67 | 2021-2024 | Myrisk, Precisetumor |
| Baxter Healthcare | $522.90 | 2020-2025 | Perclot, Tisseel, Floseal |
| Astellas Pharma US INC | $346.82 | 2022-2024 | Veozah, Cresemba |
| Bayer Healthcare Pharmaceuticals INC. | $343.10 | 2021-2023 | |
| Eisai INC. | $286.01 | 2019-2025 | |
| Myovant Sciences INC. | $211.56 | 2021-2022 | |
| Dilon Technologies, INC. | $195.82 | 2025 | Hemoblast Bellows |
| Abbvie INC. | $187.54 | 2019-2025 | |
| Pacira Pharmaceuticals Incorporated | $129.16 | 2021-2025 | Exparel |
| Therapeuticsmd, INC. | $101.59 | 2019-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $100.72 | 2025 | |
| Sumitomo Pharma America, INC. | $89.49 | 2023-2025 | Myfembree |
| Integra Lifesciences Corporation | $84.22 | 2023-2024 | Duraseal Exact Spinal Sealant System, Cusa Clarity, Codman Hakim |
| Daiichi Sankyo INC. | $81.97 | 2021-2023 | Injectafer |
| Smith+Nephew, INC. | $69.16 | 2019-2023 | Stravix Pl |
| Mayne Pharma Commercial LLC | $65.87 | 2022-2023 | |
| Genmab U.S., INC. | $57.26 | 2022-2025 | Tivdak |
| Davol INC. | $47.68 | 2024-2025 | Arista Ah Flexitip, Arista |
| Caris Mpi, INC. | $42.75 | 2025 | Mi Cancer Seek |
| Hologic Sales and Service, LLC | $36.20 | 2019-2023 | Affirm Prone Biopsy System |
| Clovis Oncology, INC. | $34.98 | 2019 | |
| Organon LLC | $30.74 | 2022-2023 | Nexplanon |
| Ethicon US, LLC | $30.02 | 2021-2022 | |
| Medtronic, INC. | $26.86 | 2022 | |
| Medical Device Business Services, INC. | $24.39 | 2025 | Enseal |
| Alexion Pharmaceuticals, INC. | $22.99 | 2022 | |
| Immunogen, INC. | $20.78 | 2023 | Elahere |
| Novartis Pharmaceuticals Corporation | $20.31 | 2023 | |
| Biom'Up Sa | $19.47 | 2019 | |
| Baudax Bio INC. | $17.90 | 2021 | |
| Sanara Medtech INC. | $17.16 | 2021 | |
| Amag Pharmaceuticals, INC. | $15.50 | 2019 | |
| Millicent US INC | $15.28 | 2024 | Femring, Intrarosa |
| Evofem Biosciences, INC. | $15.23 | 2022 | |
| Meditrina | $14.58 | 2024 | |
| Kci USA, INC. | $14.28 | 2020 | |
| Kyowa Kirin, INC. | $13.90 | 2019 | |
| Novo Nordisk INC | $13.02 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aparna Kamat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.